Early Stage China Biotech: Attracting U.S. Investment

Early stage biotechnology companies in China have shown they are capable of developing novel compounds and biologics to address difficult diseases. But they find it challenging to raise the necessary capital to develop their novel technologies.

This presentation provides a three step approach to raising capital from U.S. investors by properly positioning a China biotech for investment.

Presented by Greg Scott, who has helped launch over 30 life science companies, at the Shanghai International Biopharma Investment Forum on April 12, 2007.